A genetic targeting of CXCR4 in mouse T-ALL after disease onset could lead to a rapid, sustained disease remission, and CXCR4 antagonism is able to block human T-ALL in primary xenografts. Here, CXCR4 is linked to acute lymphoblastic leukemia.